Cosibelimab

Summary

Cosibelimab (CHEMBL4297729) is an approved antibody; indicated across 4 conditions including head and neck squamous cell carcinoma and non-small cell lung carcinoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• Indications: 4 conditions
• Clinical trials: 6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297729
Name	Cosibelimab
Type	Antibody
Max phase	4

Also known as: Ck-301, CK-301, Cosibelimab, Cosibelimab-ipdl, Tg-1501, TG-1501, Unloxcyt, COSIBELIMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
head and neck squamous cell carcinoma	4	MONDO:0010150	EFO:0000181
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
B-cell chronic lymphocytic leukemia	1	MONDO:0004948	EFO:0000095
neoplasm	1	MONDO:0005070	EFO:0000616

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE1	4
PHASE4	1
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07426484	PHASE4	NOT_YET_RECRUITING	Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
NCT04786964	PHASE3	TERMINATED	Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC
NCT03212404	PHASE1	ACTIVE_NOT_RECRUITING	Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
NCT06981806	PHASE1	NOT_YET_RECRUITING	Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma
NCT02535286	PHASE1	COMPLETED	Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter’s Transformation
NCT03778073	PHASE1	TERMINATED	Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).